Hvivo signs €7.3m contract to test common cold treatment

Study will evaluate the effect of the antiviral candidate on viral load, safety and tolerability against HRV infection in healthy volunteers

Cathal Friel, Hvivo founder and chairman. Picture: Fergal Phillips

Hvivo, the Irish pharmaceutical services company founded by Irish businessman Cathal Friel, has signed a £6.3 million (€7.28 million) contract to test a potential treatment for the common cold.

The agreement is with a biotechnology client to test its antiviral candidate using the Hvivo Human Rhinovirus (HRV\) Human Challenge Study Model.

The Phase 2a randomised, double-blinded placebo-controlled human challenge trial is planned to take place at the company’s new specialist state-of-the-art quarantine facilities in Canary ...